Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three cases
AUTOR(ES)
Ajayi, Nnennaya Anthony, Ukwaja, Kingsley Nnanna
FONTE
Rev. Soc. Bras. Med. Trop.
DATA DE PUBLICAÇÃO
2013-07
RESUMO
Artemisinin-based combination therapy-resistant malaria is rare in Sub-Saharan Africa. The World Health Organization identifies monitoring and surveillance using day-3 parasitaemia post-treatment as the standard test for identifying suspected artemisinin resistance. We report three cases of early treatment failure due to possible artemisinin-based combination therapy-resistant Plasmodium falciparum malaria. All cases showed adequate clinical and parasitological responses to quinine. This study reveals a need to re-evaluate the quality and efficacy of artemisinin-based combination therapy agents in Nigeria and Sub-Saharan Africa.
Documentos Relacionados
- Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia
- Therapeutic failure after regimen with artemether-lumefantrine combination therapy: a report of three cases in Benin City, Nigeria
- Plasmodium falciparum gametocyte carriage, sex ratios and asexual parasite rates in Nigerian children before and after a treatment protocol policy change instituting the use of artemisinin-based combination therapies
- Familial occurrence of unilateral giant breasts in Nigeria: a possible new genetic entity.
- Chloroquine resistant Plasmodium falciparum malaria in Osogbo Nigeria: efficacy of amodiaquine + sulfadoxine-pyrimethamine and chloroquine + chlorpheniramine for treatment
